Revenue
2022
2023
2024
2025
BioXcel Therapeutics, Inc. (BTAI)
Price$0.0903Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $642,000 | $2.3M | $1.4M | $375,000 | — | — | — | — | — |
| Gross profit | $478,000 | $123,000 | $120,000 | $355,000 | — | — | — | — | — |
| Gross margin | 74.45% | 5.43% | 8.70% | 94.67% | — | — | — | — | — |
| Research & development | $30.3M | $30.4M | $84.3M | $91.2M | $52.7M | $58.0M | $25.8M | $14.6M | $2.7M |
| Operating expenses | $51.1M | $69.5M | $173.2M | $160.0M | $106.9M | $82.3M | $33.6M | $20.0M | $4.5M |
| Operating income | −$50.5M | −$67.2M | −$171.8M | −$159.6M | −$106.9M | −$82.3M | −$33.6M | −$20.0M | −$4.5M |
| Operating margin | −7,859.97% | −2,967.56% | −12,447.97% | −42,572.00% | — | — | — | — | — |
| EBITDA | −$50.2M | −$66.9M | −$171.5M | −$159.3M | −$106.6M | −$82.1M | −$33.4M | −$19.9M | −$4.5M |
| EBITDA margin | −7,813.24% | −2,953.93% | −12,424.93% | −42,484.80% | — | — | — | — | — |
| Net income | −$69.9M | −$59.6M | −$179.1M | −$165.8M | −$106.9M | −$82.2M | −$33.0M | −$19.3M | −$4.5M |
| Net profit margin | −10,887.38% | −2,630.14% | −12,974.86% | −44,201.87% | — | — | — | — | — |
| Basic EPSper basic share | -$5.73 | -$23.51 | -$98.33 | -$94.72 | -$64.80 | -$60.64 | -$32.32 | -$21.12 | -$7.52 |
| Diluted EPSper diluted share | -$5.73 | -$23.51 | -$98.33 | -$94.72 | -$64.80 | -$60.64 | -$32.32 | -$21.12 | -$7.52 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Mehta Vimal | 550.29K |
Rodriguez Javier | 26.84K |
Steinhart Richard I | 26.34K |
Yocca Frank | 26.21K |
MACK DAVID J. | 20.32K |
O'Neill Vincent | 19.96K |
Wiley Matthew T. | 19.01K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 20, 2026Form 4 · 10b5-1 | Yocca FrankChief Scientific Officer | SellCommon Stock | 6.8K | $1.09 | $7.5K | 26.2K |
| May 20, 2026Form 4 · 10b5-1 | Rodriguez JavierSee Remarks | SellCommon Stock | 6.6K | $1.08 | $7.1K | 26.8K |
| May 20, 2026Form 4 · 10b5-1 | Steinhart Richard IChief Financial Officer | SellCommon Stock | 6.8K | $1.09 | $7.5K | 26.3K |
| May 20, 2026Form 4 · 10b5-1 | Mehta VimalCEO and President | SellCommon Stock | 19.4K | $1.09 | $21.2K | 69.6K |
| Dec 16, 2024Form 4 · 10b5-1 | O'Neill VincentSee Remarks | SellCommon Stock | 165 | $0.35 | $57.75 | 20.0K |